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Morphologic changes of peritoneum and expression of VEGF
in encapsulated peritoneal sclerosis rat models.
Background. Simple sclerosis consisted of a thin layer of sub-
mesothelial sclerotic tissue in peritoneal dialysis patients. En-
capsulated peritoneal sclerosis (EPS) was characterized by thick
sclerotic tissue involving vascular alterations in peritoneal dial-
ysis patients. The objective of the present study is to evaluate se-
rial morphologic changes and expressions of angiogenic factors
[i.e., vascular endothelial growth factor (VEGF), angiopietin-1
(Ang-1), and angiopoietin-2 (Ang-2)] in EPS rat models.
Methods. Twenty-four rats were given a daily intraperitoneal
injection of chlorhexidine gluconate and ethanol dissolved in
saline (CH). Nine rats were injected with CH and anti-VEGF
neutralizing antibody simultaneously. Quantitative blood ves-
sel evaluation was performed by staining for GS1-lectin. The
mRNA expression of VEGF, Ang-1, Ang-2, and their recep-
tors was evaluated by semiquantitative reverse transcription-
polymerase chain reaction (RT-PCR). Immunohistochemical
staining was performed in peritoneal vessels using anti-VEGF,
Ang-1, and Ang-2 antibodies. Hematopoietic stem cells were
detected using anti-CD34 antibody.
Results. The vessel area, diameter, and length gradually in-
creased until day 21, and then decreased. VEGF and Ang-2
mRNA expressions gradually increased until day 35. In con-
trast, Ang-1 peaked at day 21 and then decreased significantly.
VEGF blockade improved the experimental EPS. In immuno-
histochemistry, the vessels stained by VEGF and Ang-2 were
detected in subfibrous layer. CD34-positive cells were markedly
stained at day 21.
Conclusion. Neoangiogenesis was observed in a rat model of
experimental EPS. VEGF and angiopoietin/Tie system play an
important role in the neoangiogenesis in this model. An analysis
using this experimental rat model may elucidate the develop-
ment of EPS in peritoneal dialysis patients.
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Peritoneal dialysis is an attractive treatment for pa-
tients with end-stage renal failure (ESRF). However,
long-term peritoneal dialysis is associated with the de-
velopment of functional and structural alterations of the
peritoneal membrane [1]. Continuous exposure to bioin-
compatible dialysate components and repeated episodes
of bacterial peritonitis may play major roles in alter-
ations of peritoneal function and structure [1, 2]. Stru-
ijk, Krediet, and Koomen [3] and Kediet [4] reported
that changes of peritoneal function with long-term peri-
toneal dialysis were attributed to increasing of blood ves-
sel permeability and total vascular surface area in the
peritoneum. Based on previous study by Struijk et al [5],
Krediet [6], and Mateijan et al [7], we hypothesized that
vascular proliferation may be occurred in long-term peri-
toneal dialysis. This idea is supported by findings from
transforming growth factor-b (TGF-b) mesothelial cell
transfection rat model [8]. The increase of peritoneal
vascular area in peritoneal dialysis patients with ultrafil-
tration failure (UFF) might result from up-regulation of
angiogenic cytokines such as vascular endothelial growth
factor (VEGF) in the process of peritoneal dialysis.
Biopsy samples revealed a generalized thickening of the
submesothelial collagenous zone in the peritoneum in
peritoneal dialysis patients and animals [9, 10]. Other re-
ports showed that these alterations were caused by over-
production of cytokines in the peritoneal cavity [11, 12].
VEGF has been identified by both immunohistochemical
and immunobloting analyses of biopsy samples from pa-
tients with long-duration peritoneal dialysis [13]. Garosi
and Di Paolo [14] previously reported that simple scle-
rosisis consisted of a thin layer of submesothelial scle-
rotic tissue in peritoneal dialysis patients. On the other
hand, sclerosing peritonitis was characterized by thick
sclerotic tissue involving severe vascular alterations in
peritoneal dialysis patients. We hypothesized that vascu-
lar proliferation may occur in long-term peritoneal dialy-
sis and VEGF may be a key factor in this process. In this
study, we examined the critical role of VEGF by studying
the process of development of encapsulated peritoneal
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sclerosis (EPS) through VEGF in the EPS rat model and
to evaluate serial pathologic changes (i.e., neoangiogene-
sis of the peritoneum) by morphometric analysis of blood
vessels.
METHODS
Animals
Forty-one male Sprague-Dawley rats at 8 weeks of age
(225 to 275 g body weight) (Charles River Breeding Lab-
oratories, Kanagawa, Japan) were used in the present
study. All animal studies were performed according to the
National Research Council Guidelines. Twenty-four rats
were given a daily intraperitoneal injection of 3 mL/200g
body weight of 0.1% chlorhexidine gluconate and 15%
ethanol dissolved in saline (CH) [15]. Eight rats were in-
jected daily with the same dosages of saline without CH
as controls. These rats were sacrificed on days 0, 1, 3,
7, 14, 17, 21, 28, and 35. Nine rats were injected daily
with CH and anti-VEGF–specific neutralizing antibody
12 hours prior to injection of CH (4 lg intraperitoneally
three times a week) (R&D Systems, Minneapolis, MN,
USA) [16, 17]. These rats were sacrificed on days 14, 21,
and 28. The animals did not show any bacterial infection
in their ascites.
Histologic assessment
The anterior abdominal wall, liver, and mesentery were
fixed in 10% formalin and then embedded in paraffin.
The 4 lm sections obtained were stained with hema-
toxylin and eosin and Masson’s trichrome. Both parietal
and visceral peritoneal surfaces were evaluated by mor-
phometry and immunohistochemistry. The thickening of
submesothelial compact zone that was an area from the
surface of the abdominal muscle to the peritoneal cavity
was defined as interstitial fibrosis. Quantification of the
submethothelial compact zone was performed by image
analysis. The images were analyzed using a KS400 imag-
ing System, Release 3.0 (Carl Zeiss, Oberkocken, Ger-
many). The objective (×200) was positioned at random
on the sections. The microscopic image was recorded at
each of these five positions. The thickness of the subme-
sothelial compact zone was measured. Fibrosis was de-
fined as a submesothelial compact zone of more than 15
lm (the highest value recorded for control subjects).
Morphologic analysis
Sections of the anterior abdominal wall were stained
with Griffonia simplicifolia 1 (GS1)-lectin (Vector Lab-
oratories, CA, USA) as a marker of capillaries and mi-
crocirculatory vessels as previously described [18]. The
samples were exposed to 25 lg/mL fluorescent lectin for
30 minutes, rinsed twice in phosphate-buffered saline
(PBS), pH 7.4, and then mounted on the slides with
water-soluble mountant, Gel/Mount (Biomeda Corp,
CA, USA). Observations were performed with a laser
scanning confocal imaging system (LSCS) (MRC-1024)
(Bio-Rad, Hercules, CA, USA). All automatic gain con-
trols were switched off during the experiments. The
images were analyzed using a KS400 Imaging System,
Release 3.0 (Carl Zeiss). Microvascular area, diameter,
and length were evaluated in all segments of the sections.
To avoid selection bias, quantification was performed in a
predefined segment. The objective (×100) was positioned
at random on the edge of the sections. The microscopic
image was recorded at each of these five positions. The
vessel length and area in each field were measured, and
the average was calculated. The vessel diameter was also
measured for each of these 20 positions, and the average
was then calculated.
Immunohistochemical analysis
Using the same 4 lm sections, immunohistochemi-
cal analyses were performed. All sections were deparaf-
finized in xylene, followed by 100% ethanol, and then
placed in a freshly prepared methanol/0.3% H2O2 so-
lution for 15 minutes for blocking of endogenous per-
oxidase activity. Thereafter, microwave antigen retrieval
was performed with hot 0.01 mol/L-citrate buffer for
15 minutes. The sections were allowed to reach room
temperature before subsequent procedures were per-
formed. The sections were then blocked with 2% bovine
serum albumin (BSA), 2% fetal calf serum (FCS),
and 0.2% fish gelatin in 0.01 mol/L PBS, pH 7.4, for
30 minutes, followed by overnight incubation with goat
anti-human VEGF (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) (1:100), goat antihuman angiopietin-1
(Ang-1) (Santa Cruz Biotechnology) (1:200), goat an-
tihuman angiopoietin-2 (Ang-2) (Santa Cruz Biotech-
nology) (1:200), goat antihuman platelet-endothelial
cell adhesion molecule-1 (PECAM-1) (Santa Cruz
Biotechnology) (1:200) or goat antihuman CD34 (Santa
Cruz Biotechnology) (1:200) antisera at 4◦C (Table 1).
Negative staining was confirmed by incubation without
primary or secondary antibody. These sections were in-
cubated at room temperature for 30 minutes with biotiny-
lated rabbit antigoat IgG (Vector Laboratories) (1:200)
antibody and then incubated with the avidin-biotin per-
oxidase complex (Vector Laboratories) at room tempera-
ture for 30 minutes. The bound antibodies were visualized
with 3,3′-diaminobenzine containing 0.003% H2O2. Be-
tween each incubation step, sections were washed with
PBS (pH 7.4) three times, except before addition of the
primary antibodies. All sections were counterstained with
Mayer’s hematoxylin at room temperature for 3 minutes
before mounting with glycerin gelatin.
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Table 1. The role and distribution of vascular endothelial growth
factor (VEGF), angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2),
CD34, and platelet-endothelial cell adhesion molecule-1 (PECAM-1)
antibodies
Antibody Role Distribution
VEGF Proliferating factor of
endothelial cells
Endothelial cells and
infiltrating cells
Ang-1 Proliferating factor for
vascular remodeling
Endothelial cells and
infiltrating cells
Ang-2 Sprouting factor of vessels Endothelial cells and
infiltrating cells
CD34 Marker of immature and/or
mature endothelial cells
Endothelial cells and
endothelial progenitor
cells
PECAM-1 Marker of mature
endothelial cells
Endothelial cells
Reverse transcription-polymerase chain reaction
(RT-PCR) analysis of different angiogenic factors
Peritoneal samples were snap-frozen immediately af-
ter resection and stored at –80◦C for RNA extrac-
tion. Total RNA was extracted by the acid guanidinium
thiocyanate-phenol-chloroform method [19]. One micro-
gram of total RNA was reverse-transcribed using oligo
(dT) primers (Invitrogen, Carlsbad, CA, USA) and re-
verse transcriptase (Superscript II; Invitrogen). First-
strand cDNA was synthesized by priming 1 lg of total
RNA in a 20 lL RT mixture containing 4lL of 5×first-
strand buffer, and 1lL of deoxynucleotide triphosphate
(dNTP) (Invitrogen) mix containing 10 mmol/L of each
dNTP base, 2 lL of 0.1 mol/L dithiothreitol (DTT), and
200 U of reverse transcriptase. After incubation at 42◦C
for 50 minutes, the product was inactivated by heating at
90◦C for 5 minutes. To remove RNA complementary to
the cDNA, 1 lL of RNase H (Invitrogen) was added to
the product and incubated at 37◦C for 20 minutes. The
product was diluted 10 times and used for PCR. Then
5 lL of the RT product was added to reaction mixture
containing 2 lL of 10 × PCR buffer, 1.6 lL of 2.5 mmol/L
dNTP mixture, 1 U of Taq polymerase (Takara Biochem-
icals, Ohtsu, Japan) and 2.5 pmol/lL of each primer in a
final volume of 20 lL. The regions amplified by each set
of primers were as follows: rat VEGF nucleotides 26 to
336 (Gene Bank NM-03183, 310 bp), sense, 5′-ACT GGA
CCC TGG CTT TAC TGC-3′, antisense, 5′-TTG GTG
AGG TTT GAT CCG CAT G-3′; rat Ang-1, Ang-2, Tie-1,
Tie-2, and Flt-1 nucleotides as previously described [20];
rat Ang-1 nucleotides 15 to 215 (200 bp), sense, 5′-GTG
GCT GGA AAA ACT TGA GA-3′, antisense, 5′-TGG
ATT TCA AGA CGG GAT GT-3′; rat Ang-2 nucleotides
72 to 241 (169 bp), sense, 5′-GAC CAG TGG GCA TCG
CTA CG-3′, antisense, 5′-CTG GTT GGC TGA TGC
TAC TG-3′; rat Tie-1 nucleotides 123 to 392 (269 bp),
sense, 5′-TGC GAG CCC AGT CCA AGA GA-3′, an-
tisense, 5′-ACA GGG TAA CTC AAA GGC TC-3′; rat
Tie-2 nucleotides 21 to 237 (216 bp), sense, 5′-TGC CAC
CAT CAC TCA ATA CC-3′, antisense, 5′-AAA CGC
CAA TAG CAC GGT GA-3′; and rat Flt-1 nucleotides
1943 to 2155 (212 bp), sense, 5′-AGG AGA GGA CCT
GAA ACT GTC CT-3′, antisense, 5′-TTC CTG GCT
CTG CAG GCA TAG GT-3′; and rat glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) nucleotides 331
to 1038 (Gene Bank NM-017008, 707 bp), sense, 5′-ACC
ACC ATG GAG AAG GCT GG-3′, antisense, 5′-GGT
TTC TTA CTC CTT GGA GG-3′. The mixture was dena-
tured and amplified in a GeneAmp PCR System Peltier
Thermal Cycler-200 (MJ-Japan, Tokyo, Japan) under the
following conditions: 1 minute at 94◦C, 1 minute at 57 to
62◦C, and 1 minute at 72◦C for 22 to 35 cycles (annealing
temperature: GAPDH, 57◦C; Ang-1, 58◦C; VEGF, Flt-1,
Tie-1, and Tie-2, 60◦C; Ang-2, 62◦C; cycles: GAPDH, 22;
Tie-1, 28; VEGF and Tie-2, 33; Ang-2, 34; and Ang-1 and
Flt-1, 35). Negative controls (cDNA-free solutions) were
included in each reaction.
After defined cycles of PCR, 5 lL of the 20 lL reac-
tion volume was electrophoresed on 1.5% agarose gel in
1 × Tris-aceta ethylenediaminetetraacetic acid (EDTA),
and amplified bands were detected by ethidium bromide
staining. The intensity of ethidium bromide fluorescence
was obtained using Bio-Print (Vilber Lourmat, France)
and then measured using Master Scan (Scanalytics, MA,
USA). Initially, each cDNA species was amplified be-
tween 20 and 40 cycles. The optimum number of PCR
cycles for each cDNA species was determined by plotting
the PCR product yield of different cycles on a semilog-
arithmic graph and the cycle number representing the
exponential amplification was chosen for the final am-
plification. For quantification of the PCR products of all
samples, the samples were evaluated in comparison with
the PCR product for GAPDH. The fidelity of the PCR
products was also confirmed by nucleotide sequencing.
Statistical analysis
The data are presented as mean ± SD. Analysis of vari-
ance (ANOVA) and unpaired t test were used to test sta-
tistical significance. The level of significance was set at
P < 0.05.
RESULTS
Effects of CH on the structure of the peritoneum
At day 7, there was thickening in the submesothelial
layer with edema and a modest increase in cell elements.
At day 14, there were significant changes in thickening of
the peritoneum with edema, cell infiltration, and neoan-
giogenesis (Fig. 1). At day 21, these findings were marked,
and deposition of collagen was also observed in the
peritoneum. At day 28, neoangiogenesis had decreased,
although collagen fibrils had accumulated. At day 35,
fibrous tissues with cell infiltration covered the subme-
sothelial region. There were similar findings in both the
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Fig. 1. Histologic features of the anterior abdominal wall. (A) Control rat peritoneum. (B) At day 7, there is thickening of the peritoneum with
edema. (C) At day 14, with increased cellularity and angiogenesis. (D) At day 21,these findings were marked. (E) At day 28, angiogenesis had
decreased although collagen fibrils had accumulated. (F) At day 35, submesothelial region was covered by fibrous tissues with cell infiltration. (G)
At day 14, with increased cellularity and edema. Angiogenesis was improved compared with chlorhexidine gluconate and ethanol dissolved in saline
(CH) group at day 14. (H) At day 21, the thickness of the compact zone was improved compared with CH group. (I) At day 28, its finding was
marked. Masson’s trichrome staining (original magnification, ×200).
parietal and visceral peritoneal sections. No histologic
changes were observed in the control groups. Mesothe-
lial cells were detected at the peritoneal surface in control
rats, but they were not detected in CH-injected rats after
day 7. In the CH group, the thickness of the submesothe-
lial compact zone gradually increased (control 11.5 ±
1.6 lm; day 7 95.9 ± 10.6 lm; day 14 211.4 ± 40.3 lm;
day 21 284.3 ± 25.1 lm; day 28 355.3 ± 42.5 lm; and
day 35 436.9 ± 58.9 lm). While, in CH with anti-VEGF
antibody group, the thickness of the compact zone was
improved compared with the CH group (Fig. 2). There
was a remarkable difference on thickness of peritoneum
in each observation between the CH group and CH with
anti-VEGF antibody group (P < 0.01).
Quantitative analysis for blood vessel assessment
In the CH group, from day 14 to day 21, blood ves-
sels were dilated with increased branches and numbers.
From day 28 to day 35, the area of the blood vessels
decreased and the diameter of the vessels became vari-
able. The blood vessels appeared to be disconnected from
day 28 to day 35 (Fig. 3A). The vascular area showed a
peak level at day 21(0.36 ± 0.14 mm2/field; P < 0.001 vs.
day 0) and then significantly decreased at day 28(0.18 ±
0.04 mm2/field; P < 0.001 vs. day 21) and day 35(0.17 ±
0.04 mm2/field; P < 0.001 vs. day 21). The vascular diam-
eter also showed a peak level at day 21(29.1 ± 11.1 lm/
vessel; P < 0.001 vs. day 0) and then decreased at day
28(14.3 ± 4.36 lm/vessel; P < 0.001 vs. day 21) and day
35 (20.4 ± 7.48 lm/vessel; P < 0.001 vs. day 21). The
vascular length reached a peak level at day 21(68.4 ±
16.7 mm/field; P < 0.001 vs. day 0) and then decreased
at day 28(44.7 ± 13.7 mm/field; P < 0.001 vs. day 21)
(Fig. 3B). At days 28 and 35, the widths of blood ves-
sels were variable. The vascular diameter and length
at day 35 were slightly higher than those at day 28,
but the difference was not statistically significant. These
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Fig. 2. The thickness of the submesothelial compact zone. In the
chlorhexidine gluconate and ethanol dissolved in saline (CH) group,
the thickness of the submesothelial compact zone gradually increased.
In CH with anti-vascular endothelial growth factor (VEGF) antibody
group, the thickness of the compact zone was improved compared with
CH group. There was a remarkable difference on thickness of peri-
toneum in each observation between CH group and CH with anti-
VEGF antibody group. ∗P < 0.01.
findings were different from the ordinary characteristics
of peritoneal capillaries before day 21 because the blood
vessels appeared to be disconnected. In the CH with anti-
VEGF antibody group, the vascular area, diameter, and
length were gradually increased from day 14 to 28, al-
though these changes were milder than those in the CH
group. These findings were decreased significantly at days
14 and 21 compared with the CH group (P < 0.01).
Immunohistochemical analysis of the peritoneum
injected daily with CH
At day 14, Ang-1 was expressed in the endothelial
cells and infiltrating cells (Fig. 4A). Ang-2 and VEGF
were strongly expressed in the endothelial cells in deep
parts of the peritoneal tissues (Fig. 4B and C). Vascular
proliferation was diminished although thickening of the
submesothelial collagenous tissues increased at day 28.
Ang-1 expression became weak at day 28 (Fig. 4D). Ang-
2 and VEGF were strongly detected in shallow parts of
the peritoneum (Fig. 4E and F). CD34-positive cells were
markedly stained at day 21. CD34-positive and PECAM-
1–negative cells were localized in shallow regions of the
peritoneum. On the other hand, CD34- and PECAM-1–
positive cells were clustered in the superficial peritoneal
layer at day 21 (Fig. 5). There were similar findings in both
the parietal and visceral peritoneal sections. No histologic
changes were observed in the control groups.
Expression of angiogenic factor and receptor
mRNA assessment
In the CH group, the levels of VEGF mRNA expres-
sion after intraperitoneal injection of CH were signifi-
cantly higher at day 21 (mean ± SD 42.3 ± 9.9 optical
density; P = 0.088 vs. day 0) and at day 35 (52.3 ± 11.2;
P = 0.005 vs. day 0) than those at day 0 (Fig. 6A and
B, panel a). The levels of Ang-2 mRNA expression were
significantly increased at day 28 (30.6 ± 12.8; P = 0.0433
vs. day 0) and at day 35 (36.8 ± 6.88; P = 0.0092 vs. day 0)
(Fig. 6A and B, panel d). In contrast, the levels of Ang-
1 mRNA expression decreased significantly at day 28
(18.4 ± 5.04; P = 0.0383 vs. day 0) and at day 35(18.9 ±
5.05; P = 0.047 vs. day 0) (Fig. 6A and B, panel c).
The levels of Flt-1 mRNA expression, a marker of the
VEGF receptor, were significantly increased at day 21
(50.4 ± 6.08; P = 0.003 vs. day 0) and day 35 (49.7 ± 9.25;
P = 0.0034 vs. day 0) (Fig. 6A and B, panel b). Both Tie-1
and Tie-2 mRNA expressions were elevated to twice the
levels of control rats at day 35. Tie-2 mRNA expression
increased significantly at day 35 (39.1 ± 9.03; P = 0.013
vs. day 0) (Fig. 6A, and B, panels e and f).
In the CH with anti-VEGF antibody group, the levels
of VEGF and Flt-1 mRNA expression were gradually
decreased from day 14 to 28 and statistically significant
compared with CH (Fig. 6A and B, panels a and b). The
levels of Ang-2, Tie-1, and Tie-2 mRNA expression were
gradually decreased, with a significant difference from
the CH group (Fig. 6A and B, panels d, e, and f). However,
Ang-1 mRNA expression was not statistically significant
compared with CH (Fig. 6A and B, panel c).
DISCUSSION
Previous studies demonstrated that many factors such
as endotoxin contamination in the dialysate [21], acetate
dialysate [21, 22], the use of antiseptics [22, 23], advanced
glycation end-products (AGEs) [23], and carbonyl mod-
ifications of peritoneal tissue [24] are involved in the
pathogenesis of peritoneal fibrosis/sclerosis, but the un-
derlying mechanisms in the development of EPS remain
unclear. Although CH is not clinically used in peritoneal
dialysis, we employed CH as a nonspecific inducer for ex-
perimental EPS to approach the pathogenesis [25]. EPS
is produced by not only long-term peritoneal dialysis
but also by other diseases [26–28] partly related to ab-
dominal operations [26, 27], suggesting that nonspecific
peritoneal stimulation may induce EPS. Therefore, we
thought that the pathologic findings of developing EPS
were not always uniform and many factors take part in
the developing EPS. Furthermore, one of the critical dif-
ferences between simple sclerosis and EPS is due to the
involvement of cellular infiltration in the sclerotic tissues
[14]. Although this model does not completely mimic hu-
man disease, the EPS rat model by daily repeated in-
traperitoneal injections of CH should be appropriate for
our purpose in order to clarify the influence of cellular
infiltration.
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Fig. 3. Quantitative analysis for blood vessel assessment. (A) Sections stained for Griffonia simplicifolia 1 (GS1)-lectin, a marker for capillaries
and the microcirculatory vessels, using a laser scanning confocal imaging system. Panels a to f are chlorhexidine gluconate and ethanol dissolved
in saline (CH) group. Panel a is control on day 35, panel b is at day 7, panel c is at day 14, and panel d is at day 21. From day 14 to day 21, blood
vessels were dilated with increased branches and numbers. From day 28 (panel e) to day 35 (panel f), the area of blood vessels decreased and the
diameter of the vessels became variable. Panels g to I are CH with anti-vascular endotheial growth factor (VEGF) antibody group. Panel g is at
day 14, panel h is at day 21, and panel I is at day 28. From day 14 to day 21, dilatation of blood vessels were improved compared with CH group
noticeably (magnification, ×100). (B) In the CH group, panel a (vascular area) (mm2/field), panel b (vascular diameter) (lm/vessel), and panel c
(vascular length) (mm/field) showed peak levels at day 21 and then decreased at day 28 and day 35. The vascular diameter and length at day 35 were
slightly higher than those at day 28, but the difference was not significant. In the CH with anti-VEGF antibody group, the vascular area, diameter
and length were gradually increased from days 14 to 28. These changes were milder than those in the CH group. From days 14 to 21, vascular area,
diameter, and length were improved compared with the CH group #P < 0.001 vs. CH group; ∗P < 0.001 vs. day 0; ∗∗P < 0.001 vs. day 21.
In the present study, we focused on the role of VEGF
by evaluation of serial morphologic changes and expres-
sion of angiogenic factors in this model. Vascular pro-
liferation, thickening of interstitial fibrosis, and increase
of VEGF expression were observed in this study. Both
VEGF and angiopietin are well known to be essential
for vascular development [29–33]. In general, VEGF
plays critical roles in endothelial cell proliferation, mi-
gration [34–36], and expression of protease [37], while
the angiopietin/Tie pathway contributes to the remodel-
ing and formation of a supportive structure around the
nascent blood vessels [31, 38–41]. Our findings revealed
that VEGF blockade by the neutralizing antibody signif-
icantly improved the experimental EPS, suggesting that
VEGF activation in the early phase may be critical for
the development of this disease with neoangiogenesis. In
fact, the VEGF blockade significantly decreased Ang-
2, Tie-1, and Tie-2 expression. These findings implied
that VEGF activation may stimulate the angiopietin/Tie
pathway in this disease. However, we did not find a
significant decrement of Ang-1 expression in VEGF
blockade. Ang-1/Tie-2 interaction is known to be a sta-
bilizer of normal adult vessels [38–41], suggesting that
VEGF may not regulate Ang-1 expression in this disease.
Since VEGF blockade also decreased VEGF and Flt-1
expressions after day 14, initial VEGF activation may
play key role in further VEGF production. The VEGF
production by mesothelial cells [42, 43] has recently been
reported. However, the cellular sources of VEGF may be
different in each pathologic stage of this disease. In fact,
VEGF expressions after day 14 were detected in both
capillary endothelial cells and infiltrating cells.
Several previous studies [39, 40] reported that Ang-2
promotes sprouting of new blood vessels in the pres-
ence of VEGF. Ang-1 mRNA levels were significantly
decreased at days 28 and 35, although the levels of VEGF
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Day 14
Day 28
Fig. 4. Immunohistochemical analysis of the anterior abdominal wall injected daily with chlorhexidine gluconate and ethanol dissolved in saline
(CH). (A) At day 14, angiopietin-1 (Ang-1) was expressed in the endothelial cells and infiltrating cells. (B) At day 14, angiopietin-1 (Ang-2) and
vascular endothelial growth factor (VEGF) (C) were strongly expressed in the endothelial cells in deep parts of the peritoneal tissues. (D) At day
28, Ang-1 expression became weak compared with (A). At day 28, the vascular proliferation was diminished, but (E) Ang-2 and (F) VEGF were
strongly detected in shallow parts of the peritoneum (magnification, ×200).
Superficial layer
Shallow region
(× 200) 
(× 400) 
CD31CD34
Fig. 5. Immunohistochemical analysis of anterior abdominal wall injected daily with chlorhexidine gluconate and ethanol dissolved in saline
(CH). (A) CD34 staining at day 21 (magnification, ×200). (B) CD34 staining at day 21 (magnification ×400). (C) Platelet-endothelial cell adhesion
molecule-1 (PECAM-1) staining at day 21 (magnification ×200). (D) PECAM-1 staining at day 21(magnification ×400). CD34-positive and PECAM-
1–negative cells were localized in shallow regions of the peritoneum. CD34- and PECAM-1–positive cells were clustered in the superficial peritoneal
layer.
1934 Io et al: Neoangiogenesis through VEGF in EPS rat models
VEGF
Flt-1
Ang-1
Ang-2
Tie-1
Tie-2
GAPDH
0d 7d 14d 21d 28d 35d 14d 21d 28d
1 2 3 4 5 6 7 8 9
CH+ anti-VEGF Ab
A
CH
CH+ anti-VEGF
0
20
40
60
0 7 14 21 28 35 d
(a) VEGF
*
*
# # #
A.U
0
20
40
60
0 7 14 21 28 35 d
(b) Flt-1
* *
#
#
A.U
0
20
40
0 7 14 21 28 35 d
(c) Ang -1
* *
A.U
0
20
40
0 7 14 21 28 35 d
(d) Ang -2
*
*
A.U
0
20
10
30
0 7 14 21 28 35 d
(e) Tie-1
A.U
# #
#
#
0
20
40
0 7 14 21 28 35 d
(f) Tie -2
*
A.U
#
#
B
Fig. 6. Gene expression of vascular endothelial growth factor (VEGF), Flt-1, angiopietin-1 (Ang-1), angtiopietin (Ang-2), Tie-1, Tie-2, and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) analyzed by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR).
Total RNA fractions extracted from isolated peritoneum in each stage of peritonitis. PCR products were resolved on 1.5% agarose gel containing
ethidium bromide. (A) Gels shown are representative of three to four experiments. Lane 1, control; lanes 2 through 6, a daily intraperitoneal injection
of chlorhexidine gluconate and ethanol dissolved in saline (CH), days 7, 14, 21, 28, and 35, respectively. Lanes 7 through 9, a daily intraperitoneal
injection of CH with anti-VEGF antibody three times a week. (B) The bands are quantified by densitometric scanning and corrected with GAPDH
expression (arbitrary unit). Panel a is VEGF; panel b is Flt-1; panel c is Ang-1; panel d is Ang-2; panel e is Tie-1 and panel f is Tie-2. In CH with
anti-VEGF antibody group, the levels of VEGF, Flt-1, Ang-2, Tie-1, and Tie-2 mRNA expression were gradually decreased from day 14 to 28 and
statistically significant compared with CH. However, Ang-1 mRNA expression was not statistically significant compared with CH. Data represent
the mean ±SD of three to four different experiments. ∗P < 0.01 vs. day 0; #P < 0.01 vs. CH.
and Ang-2 mRNA expression increased elevated pro-
gressively and remained in the late phase. Ang-2 was
secreted from endothelial cells and infiltrating cells. Ang-
1 was secreted mainly from endothelial cells. According
to these results, it is postulated that the sprouted ves-
sels were destabilized and immature. It has been shown
that Tie-1 and Tie-2 gene disruptions play an important
role in endothelial cell differentiation and the mainte-
nance of blood vessel integrity [31]. However, Tie recep-
tors show no proliferative mediation on endothelial cells
[32]. The present findings showed that Tie-1 and Tie-2
mRNA levels peaked at day 35 in the regenerative peri-
toneum without endothelial cell proliferation. An imbal-
ance between Ang-1 and Ang-2 during progression of
neoangiogenesis may induce the disappearance of blood
vessels at the late stage by obstruction of the immature
vessels resulting from circulation insufficiency because
of a bleeding tendency, leakage of plasma, including fib-
rin, and advanced apoptosis or necrosis of endothelial
cells. Neoangiogenesis and disappearance of vessels were
detected in deep parts of the peritoneal tissues. More-
over, infiltrating cells in shallow parts of such tissues at
the late stage consisted predominantly of macrophages,
which were intensely positive for VEGF and Ang-2. In-
terestingly, CD34-positive cells, a marker of endothelial
progenitor cells, were also observed in shallow parts of
the peritoneum in the form of a cluster formation in this
study. Recently, circulating endothelial progenitor cells
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have been isolated from peripheral blood and found to
contribute to postnatal vasculogenesis in adults [44]. In
addition, hematopoietic stem cells directly promoted mi-
gration of endothelial cells in vivo and in vitro [45]. It is
postulated that hematopoietic stem cells may be related
to vascular proliferation of peritoneal sclerosis in shallow
parts of the peritoneal tissues. There may be two different
mechanisms for vascular proliferation in peritoneal scle-
rosis. Vasculogenesis in the form of embryonic vascular
network formation in the prenatal stage might occur in
shallow parts of the peritoneal tissues. Angiogenesis in
the form of branching from existing vessels might occur
in deep parts of the peritoneal tissues.
Cellular infiltrations of leukocytes, erythrocytes,
macrophages, and giant cells in sclerotic tissues are criti-
cal pathologic findings in EPS [46]. Mesothelial cells [47]
have a high fibrinolytic capacity and play an essential role
in maintaining the balance between production and reab-
sorption of fibrin. It is common to observe exudates rich
in fibrin coating the peritoneal surface. If the fibrinolytic
capacity of the mesothelium is compromised for too long,
fibrin production and organization are established on a
large scale, which favors development of EPS [48]. VEGF
binds specifically and saturably to fibrinogen and fibrin
with high affinity, and this may affect the localization and
activity of VEGF at sites of tissue injury [49]. Previous
studies have suggested that fibrin deposition plays an im-
portant role in tissue fibrosis [50, 51]. Fibrin deposition
in the tissue matrix induces recruitment of inflammatory
cells, macrophages, and fibroblasts, and leads to the syn-
thesis of extracellular matrix [51]. Therefore, it is spec-
ulated that accumulating fibrin deposition by increasing
VEGF induced development EPS from simple sclerosis.
Indeed, accumulating fibrin was observed in our experi-
mental EPS rat model at days 28 and 35. No EPS rat with
CH was observed in the early stage. In addition, 50% of
rats with CH showed EPS at day 35. Therefore, we think
that simple sclerosis may be a prestage of EPS. In this
study, VEGF blockade by the neutralizing antibody sig-
nificantly improved neoangiogenesis and submesothelial
thickening. Since VEGF blockade improved the thick-
ening of interstitial peritoneum, VEGF also may elicit
peritoneal fibrosis. Margetts et al [8] reported that find-
ings in a peritoneal sclerosis rat model with gene transfer
of TGF-b1 to the peritoneum are similar to those in our
present model in which interstitial fibrosis following in-
creased infiltration of cells and neoangiogenesis was ob-
served. Although activated TGF-b1 plays an important
role in maturation of vessels [52], TGF-b1 may indirectly
promote angiogenesis through the production of angio-
genic cytokines such as VEGF [53, 54]. Thus, the patho-
genesis of our model may involve TGF-b1 pathway.
It appears that VEGF may play a critical role in caus-
ing EPS. These results suggest that antiangiogenic factors
such as VEGF blockade might prevent lethal peritoneal
damage in patients with long-duration peritoneal dialy-
sis. It will be necessary to further examine the relation-
ship between neoangiogenesis and interstitial fibrosis in
the peritoneum during chronic inflammation induced by
some chemical compounds and/or microorganisms rather
than CH in the future.
ACKNOWLEDGMENT
We thank Yusuke Suzuki M.D., Division of Nephrology, Depart-
ment of Internal Medicine, Juntendo University, for providing useful
suggestions and discussions in this manuscript.
Reprint requests to Yasuhiko Tomino, Division of Nephrology, De-
partment of Internal Medicine, Juntendo University School of Medicine,
2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
E-mail: yasu@med.juntendo.ac.jp
REFERENCES
1. DAVIES SJ, BRYAN J, PHILLIPS L, et al: Longitudinal changes in peri-
toneal kinetics: The effects of peritoneal dialysis and peritonitis.
Nephrol Dial Transplant 11:498–506, 1996
2. SELGAS R, FERNANDEZ-REYES MJ, BOSQUE E, et al: Functional
longevity of the human peritoneum: How long is continuous peri-
toneal dialysis possible? Results of a prospective median long-term
study. Am J Kidney Dis 23:64–73, 1994
3. STRUIJK DG, KREDIET RT, KOOMEN GCM, et al: A prospective study
of peritoneal transport in CAPD patients. Kidney Int 45:1739–1744,
1994
4. KREDIET RT: Evaluation of peritoneal membrane integrity. J
Nephrol 10:238–244, 1997
5. STRUIJK DG, KREDIET RT, KOOMEN GCM, et al: Functional charac-
teristics of the peritoneal membrane in long-term continuous am-
bulatory peritoneal dialysis. Nephron 59:213–220, 1991
6. KREDIET RT: Prevention and treatment of peritoneal dialysis mem-
brane failure. Adv Ren Replace Ther 5:212–217, 1998
7. MATEIJSEN MAM, VAN DER WAL AC, HENDRIKS PMEM, et al: Vas-
cular and interstitial changes in the peritoneum of CAPD patients
with peritoneal sclerosis. Perit Dial Int 19:517–525, 1999
8. MARGETTS PJ, KOLB M, HOFF CM, et al: Gene transfer of transform-
ing growth factor-beta1 to the rat peritoneum: Effects on membrane
function. J Am Soc Nephrol 12:2029–2039, 2001
9. WILLIAMS JD, CRAIG KJ, TOPLEY N, et al, on behalf of the Peritoneal
Biopsy Study Group: Morphologic changes in the peritoneal mem-
brane of patients with renal disease. J Am Soc Nephrol 13:470–479,
2002
10. NAKAMOTO M: Pathogenesis of peritoneal fibrosis and peritoneal
small vessel changes. Perit Dial Int 16 (Suppl 1):S39–S41, 1996
11. ZWEERS MM, DE WAART DR, SMIT W, et al: Growth factors VEGF
and TGF-beta1 in peritoneal dialysis. J Lab Clin Med 134:124–132,
1999
12. LAI KN, LAI KB, LAM CW, et al: Changes of cytokine profiles during
peritonitis in patients on continuous ambulatory peritoneal dialysis.
Am J Kidney Dis 35:644–652, 2000
13. COMBET S, MIYATA T, MOULIN P, et al: Vascular proliferation and
enhanced expression of endothelial nitric oxide synthase in hu-
man peritoneum exposed to long term peritoneal dialysis. J Am
Soc Nephrol 11:717–728, 2000
14. GAROSI G, DI PAOLO N: Morphological aspects of peritoneal scle-
rosis. J Nephrol 14 (Suppl 4): S30–S38, 2001
15. ISHII Y, SAWADA T, SHIMIZU A, et al: An experimental sclerosing
encapsulating peritonitis model in mice. Nephrol Dial Transplant
16:1262–1266, 2001
16. TAMARAT R, SILVESTRE J, KUBIS N, et al: Endothelial nitric oxide
synthase lies downstream from angiotensin II-induced angiogenesis
in ischemic hindlimb. Hypertension 39:830–835, 2002
17. IBA O, MATSUBARA H, NOZAWA Y, et al: Angiogenesis by implanta-
tion of peripheral blood mononuclear cells and plates into ischemic
limbs. Circulation 106:2019–2025, 2002
1936 Io et al: Neoangiogenesis through VEGF in EPS rat models
18. HANSEN-SMITH FM, WATSON L, LU DY, GOLDSTEIN I: Griffonia sim-
plicifolia 1, fluorescent tracer for microcirculatory vessels in nonper-
fused thin muscles and sectioned muscle. Microvasc Res 36:199–215,
1988
19. CHOMCZYNSKI P, SACCHI N: Single-step method of RNA isolation by
acid guanidinium thiocyanate. Anal Biochem 162:156–159, 1987
20. SATO T, EL-ASSAL ON, ONO T, et al: Sinusoidal endothelial cell pro-
liferation and expression of angiopoietin/Tie family in regenerating
rat liver. J Hepatol 34:690–698, 2001
21. AFTHENTOPOULOS IE, PASSADAKIS P, OREOPOULOS DG, et al: Scleros-
ing peritonitis in continuous ambulatory peritoneal dialysis patients.
Adv Ren Replace Ther 5:157–167, 1998
22. LO WK, CHAN KT, LEUNG AC, et al: Sclerosing peritonitis compli-
cating prolonged use of chlorhexidine in alcohol in the connection
procedure for continuous ambulatory peritoneal dialysis. Perit Dial
Int 11:166–172, 1991
23. NAKAYAMA M, KAWAGUCHI Y, YAMADA K, et al: Immunohistochem-
ical detection of advanced glycosylation end-products in the peri-
toneum and its possible pathophysiological role in CAPD. Kidney
Int 51:182–186, 1997
24. MIYATA T, HORIE K, UEDA Y, et al: Advanced glycation and lipidox-
idation of the peritoneal membrane: Respective roles of serum and
peritoneal fluid reactive carbonyl compounds. Kidney Int 58:425–
435, 2000
25. NISHINO T, MIYAZAKI M, ABE K, et al: Antisense oligonucleotides
against collagen-binding stress protein HSP47 suppress peritoneal
fibrosis in rats. Kidney Int 64:887–896, 2003
26. COHEN O, ABRAHAMSON J, BEN-ARI J, et al: Sclerosing encapsulat-
ing peritonitis: Primary and secondary forms. J Clin Gastroenterol
22:54–57, 1996
27. DONAL M, PARTHI S, JOHN O, et al: Sclerosing encapsulating peritoni-
tis after orthotopic liver transplantation. Am J Surg 182:151–154,
2001
28. RAJAGOPAL A, RAJAGOPAL R: Conundrum of cocoon: Report of a
case and review of the literature. Dis Colon Rectum 46:1141–1143,
2003
29. CARMELIET P, MACKMAN N, MOONS L, et al: Role of tissue factor in
embryonic blood vessel development. Nature 383:73–75, 1996
30. FERRARA N, CARVER-MOORE K, CHEN H, et al: Heterozygous embry-
onic lethality induced by targeted inactivation of the VEGF gene.
Nature 380:439–442, 1996
31. SATO TN, TOZAWA Y, DEUTSCH U, et al: Distinct roles of the receptor
tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature
376:70–74, 1995
32. PURI MC, ROSSANT J, ALITALO K, et al: The receptor tyrosine kinase
TIE is required for integrity and survival of vascular endothelial
cells. EMBO J 14:5884–5891, 1995
33. RODEWALD HR, SATO TN: Tie-1, a receptor tyrosine kinase essential
for vascular endothelial cell integrity, is not critical for the develop-
ment of hematopoietic cells. Oncogene 12:397–404, 1996
34. CONNOLLY DT, HEUVELMAN DM, NELSON R, et al: Tumor vascular
permeability factor stimulates endothelial cell growth and angio-
genesis. J Clin Invest 84:1470–1478, 1989
35. LEUNG DW, CACHIANES G, KUANG WJ, et al: Vascular endothelial
growth factor is a secreted angiogenic mitogen. Science 246:1306–
1309, 1989
36. SENGER DR, LEDBETTER SR, CLAFFEY KP, et al: Stimulation of en-
dothelial cell migration by vascular permeability factor/vascular en-
dothelial growth factor through cooperative mechanisms involving
the ab 3 integrin, osteopontin, and thrombin. Am J Pathol 149:293–
305, 1996
37. PEPPER MS, FERRARA N, ORCI L, et al: Vascular endothelial growth
factor (VEGF) induces plasminogen activators and plasminogen ac-
tivator inhibitor-1 in microvascular endothelial cells. Biochem Bio-
phys Res Commun 181:902–906, 1991
38. KOBLIZEK TI, WEISS C, YANCOPOULOS GD, et al: Angiopoietin-1 in-
duces sprouting angiogenesis in vitro. Curr Biol 8:529–532, 1998
39. MAISONPIERRE PC, SURI C, JONES PF, et al: Angiopoietin-2, a nat-
ural antagonist for Tie2 that disrupts in vivo angiogenesis. Science
277:55–60, 1997
40. HANAHAN D: Signaling vascular morphogenesis and maintenance.
Science 277:48, 1997
41. DAVIS S, ALDRICH TH, JONES PF, et al: Isolation of angiopoietin-1, a
ligand for the TIE2 receptor, by secretion-trap expression cloning.
Cell 87:1161–1169, 1996
42. HOFF CM, INMAN KL, PISCOPO D, et al: TGF-beta mediated produc-
tion of VEGF by rat primary mesothelial cells. J Am Soc Nephrol
11:310A, 2000
43. HA H, CHA MK, CHOI HN, et al: Effects of peritoneal dialysis so-
lutions on the secretion of growth factors and extracellular ma-
trix proteins by human peritoneal mesothelial cells. Perit Dial Int
22:171–177, 2002
44. ASAHARA T, MASUDA H, TAKAHASHI T, et al: Bone marrow origin
of endothelial progenitor cells responsible for postnatal vasculoge-
nesis in physiological and pathological neovascularization. Circ Res
85:221–228, 1999
45. TAKAKURA N, WATANABE T, SUENOBU S, et al: A role for hematopoi-
etic stem cells in promoting angiogenesis. Cell 102:199–209, 2000
46. GAROSI G, PAOLO D. Peritoneal sclerosis: One or two nosological
entities? Semin Dial 13:297–308, 2000
47. IVARSSON ML, HOLMDAHL L, FALK P, et al: Characterization and
fibrinolytic properties of mesothelial cells isolated from peritoneal
lavage. J Clin Lab Invest 58:195–203, 1998
48. DOBBIE JW: Serositis: Comparative analysis of histological findings
and pathogenetic mechanisms in non-bacterial serosal inflamma-
tion. Perit Dial Int 13:256–259, 1993
49. SAHNI A, FRANCIS CW: Vascular endothelial growth factor binds to
fibrinogen and fibrin and stimulates endothelial cell proliferation.
Blood 96:3772–3778, 2000
50. BROWN LF, DVORAK BLF, DVORAK HF, et al: Leaky vessels, fibrin de-
position and fibrosis: A sequence of events common to solid tumors
and too many other types disease. Am Rev Respir 140:1104–1107,
1989
51. KISHIMOTO C, KITAZAWA M, HITISHI T: Interstitial fibrin-fibronectin
deposition with T cell infiltrates precedes fibrosis in murine viral
myocarditis. Int J Exp Pathol 79:417–423, 1998
52. FOLKMANN J, D’AMORE PA: Blood vessel formation: What is its
molecular basis? Cell 87:1153–1155, 1996
53. EDMUND Y, YANG, HAROLD L, MOSES: Transforming growth factor
b1-induced changes in cell migration, proliferation, and angiogen-
esis in the chicken chorioallantoic membrane. J Cell Biol 111:731–
741, 1990
54. PERTOVAARA L, KAIPAINEN A, MUSTONEN T, et al: Vascular endothe-
lial growth factor is induced in response to transforming growth
factor-b in fibroblastic and epithelial cells. J Biol Chem 269:6271–
6274, 1994
